Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Acq. announced
Director departure
Quarterly results
VBI VACCINES INC. (VBIV) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2016 8-K Quarterly results
05/09/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction ● SciVac Therapeutics changes its name to VBI Vaccines ● Combined company to begin trading on The NASDAQ Capital Market under the symbol “VBIV” ● Combined company is a biotechnology company with a licensed hepatitis B vaccine and a pipeline of novel technologies that seek to expand vaccine protection in large underserved markets CAMBRIDGE, MA – VBI Vaccines Inc., a Delaware corporation , and SciVac Therapeutics Inc., a British Columbia corporation , are pleased to announce the completion of their previously announced merger transaction, whereby SciVac acquired VBI. VBI survives the merger as a wholly owned subsidiary of SciVac. Upon completion of the merger, SciVac changed its name to VBI Vacci...",
"Additional Details Relating to the SciVac Therapeutics and VBI Vaccines Merger Transaction ● SciVac Therapeutics changed its name to VBI Vaccines ● On May 6, 2016, each share of VBI Vaccines common stock was converted into the right to receive 0.520208 common shares of post-merger VBI Vaccines ● On May 9, 2016, the combined entity began trading on The NASDAQ Capital Market under the symbol “VBIV” CAMBRIDGE, MA – VBI Vaccines Inc., a Delaware corporation , and SciVac Therapeutics Inc., a British Columbia corporation , are pleased to announce the completion of the previously announced merger transaction, whereby SciVac acquired VBI. VBI survives the merger as a wholly-owned subsidiary of SciVac. Listing Information SciVac changed its name to VBI Vaccines Inc. and the combin..."
04/28/2016 8-K Form 8-K - Current report
04/14/2016 8-K Form 8-K - Current report
03/30/2016 8-K Other Events
03/29/2016 8-K Form 8-K - Current report
03/21/2016 8-K Form 8-K - Current report
03/07/2016 8-K Form 8-K - Current report
03/03/2016 8-K Form 8-K - Current report
03/02/2016 8-K Form 8-K - Current report
02/09/2016 8-K Form 8-K - Current report
02/04/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines Partners with the Canadian CMV Foundation to Raise Congenital Cytomegalovirus Awareness CAMBRIDGE, MA – VBI Vaccines Inc. is proud to announce its continued sponsorship support of Le Classique , the Canadian CMV Foundation’s largest annual fundraiser. Now in its fourth year, Le Classique is a 3-on-3 ball hockey tournament being held in Winnipeg, Canada on February 5th and 6th, 2016, in support of cytomegalovirus awareness. “We’re thrilled to be supporting Rob Tetrault and the Canadian CMV Foundation’s efforts to promote CMV awareness and prevention strategies,” said Jeff Baxter, VBI’s President and CEO. “VBI maintains strong ties to Canada – our research facilities and the majority of our workforce are located in Ottawa, Ontario. We believe that more can be done to raise the ..."
01/26/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present at the BIO CEO & Investor Conference CAMBRIDGE, MA – VBI Vaccines Inc. is scheduled to present at the BIO CEO & Investor Conference on Tuesday, February 9th, 2016 at 1:00 PM ET. The event is being held at the Waldorf Astoria in . During the presentation, Jeff Baxter, VBI’s President and CEO, will provide an overview of VBI and its platform technologies , and will summarize recent developments in the company’s pipeline of vaccine candidates . Mr. Baxter will also discuss VBI’s planned merger with SciVac Therapeutics . SciVac’s flagship product, Sci-B-Vac™ , is a commercial hepatitis B vaccine approved for use in fifteen countries. “We expect 2016 to be a transformative year for VBI,” said Mr. Baxter. “We have been making excellent progress in advancing and exp..."
01/15/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present at the Noble Financial Emerging Growth Investor Conference CAMBRIDGE, MA – VBI Vaccines Inc. is scheduled to present at the Noble Financial Emerging Growth Investor Conference on Monday, January 18 th , 2016 at 10:00 AM ET. The event is being held at the Club Med in Sandpiper Bay, FL. During the presentation, Nell Beattie, VBI’s Director, Corporate Development and Investor Relations, will provide an overview of VBI and its platform technologies , and will summarize recent developments in the company’s pipeline of vaccine candidates. Ms. Beattie will also discuss VBI’s planned merger with SciVac Therapeutics , including SciVac’s flagship product, Sci-B-Vac™ , a commercial hepatitis B vaccine. For additional information, or to schedule a one-on-one meeting with..."
12/22/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "First Amendment to Agreement and Plan of Merger"
12/11/2015 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Director Services Agreement with Scott Requadt"
11/25/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present at the LD Micro Conference CAMBRIDGE, MA – VBI Vaccines is scheduled to present at the Eighth Annual LD Micro Conference on Thursday, December 3rd , 2015 at 1:30 PM ET . The event is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. During the presentation, Jeff Baxter, VBI’s President and CEO, will provide an overview of VBI and its platform technologies , and will summarize recent developments in the company’s cytomegalovirus , glioblastoma multiforme , and respiratory syncytial virus vaccine programs. Mr. Baxter will also discuss VBI’s planned merger with SciVac Therapeutics , including SciVac’s flagship product, Sci-B-Vac™ , which is a commercial hepatitis B vaccine. “We continue to make great strides in advancing our pipeline of preventat..."
11/20/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology CAMBRIDGE, MA – VBI Vaccines Inc. today presented an update and new data supporting its glioblastoma multiforme cancer immunotherapy program at the European Society for Medical Oncology Immuno-Oncology Symposium."
11/12/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Conference Call Transcript"
11/06/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present Update and New Data Supporting its RSV and CMV Vaccine Programs at the World Vaccine Congress Europe CAMBRIDGE, MA – VBI Vaccines Inc. is scheduled to present at the 16 th Annual World Vaccine Congress Europe on Tuesday, November 10 th , 2015 at 6:30 AM ET . The event is being held at the Silken Puerta América in Madrid, Spain."
11/05/2015 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Joint Conference Call Presentation Materials"
11/04/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "VBI Vaccines and SciVac Therapeutics To Live Webcast Joint Conference Call For Shareholders to Discuss Proposed Merger CAMBRIDGE, MA and VANCOUVER, BRITISH COLUMBIA – As previously announced, VBI Vaccines Inc. and SciVac Therapeutics Inc. will host a joint conference call for their respective shareholders at 3:00 P.M. Eastern Time on Thursday, November 5, 2015. The call will include a live webcast and be hosted by Jeff Baxter, President & CEO of VBI, and Dr. Curtis Lockshin, CEO of SciVac, who will together discuss the previously announced entry into a merger agreement whereby, subject to the satisfaction of certain conditions, a wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving as a wholly owned subsidiary of SciVac. The conference call will provide shar..."
10/30/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "To Hold Joint Conference Call For Shareholders to Discuss Proposed Merger CAMBRIDGE, MA and VANCOUVER, BRITISH COLUMBIA – VBI Vaccines Inc. and SciVac Therapeutics Inc. will host a joint conference call for their respective shareholders at 3:00 P.M. Eastern Time on Thursday, November 5, 2015. The call will be hosted by Jeff Baxter, President & CEO of VBI, and Dr. Curtis Lockshin, CEO of SciVac, who will together discuss the previously announced entry into a merger agreement whereby, subject to the satisfaction of certain conditions, a wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving as a wholly owned subsidiary of SciVac. The conference call will provide shareholders of VBI and SciVac with an opportunity to ask questions regarding the proposed merger. Th..."
10/26/2015 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger",
"SciVac Therapeutics Enters into Agreement to Acquire VBI Vaccines"
10/08/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines Announces Development of a Novel Glioblastoma Immunotherapy Candidate"
09/24/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present at the 15 th Annual Biotech in Europe Forum CAMBRIDGE, MA – VBI Vaccines Inc. is scheduled to present at the Sachs Associates’ 15 th Annual Biotech in Europe Forum on Tuesday, September 29 th at 6:45 AM ET . The event is being held at the Congress Center Basel in Basel, Switzerland. Jeff Baxter, VBI’s President and CEO, will provide an overview of VBI's business during his presentation. In addition, Mr. Baxter will participate in a vaccines panel discussion on September 29 th at 3:45 AM ET . The Biotech in Europe Forum brings together a cross-section of early-stage, late-stage, and public companies with leading investors, analysts, money managers, and pharmaceutical licensing executives. For more information, visit: http://bit.ly/sachs-2015 Event Details ● Ev..."
09/14/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "VBI Vaccines Promotes Dr. David E. Anderson to Chief Scientific Officer CAMBRIDGE, MA – VBI Vaccines Inc. is pleased to announce the promotion of Dr. David E. Anderson, Ph.D., to Chief Scientific Officer. Dr. Anderson has led VBI’s research and development activities since he joined the company full time in 2009 from Harvard Medical School, where he served as a member of the faculty. While at Harvard, Dr. Anderson participated in the development of a multi-disciplinary research program focused on elucidating mechanisms by which inflammation is regulated within the central nervous system, with relevance to a variety of human neurodegenerative diseases, including brain tumors, multiple sclerosis, and Alzheimer’s disease. Prior to joining Harvard’s faculty, Dr. Anderson was a research immuno..."
09/08/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines Awarded NRC-IRAP Funding to Leverage its eVLP Platform in the Development of a Novel RSV Vaccine Candidate CAMBRIDGE, MA and Ottawa, ON – VBI Vaccines Inc. has been awarded up to $350,000 CAD in grant funding by the National Research Council-Industrial Research Assistance Program to apply VBI’s eVLP Platform in the development of a respiratory syncytial virus vaccine candidate. NRC-IRAP is a Canadian government-sponsored organization that provides technical and business advisory services and financial contributions to support the development and commercialization of innovative technologies developed in Canadian R&D facilities. RSV is a respiratory virus that infects the lungs and airways and can cause serious disease in infants and older adults. According to the U.S. Centers ..."
09/03/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present at the Rodman & Renshaw 17 th Annual Global Investment Conference CAMBRIDGE, MA – VBI Vaccines Inc. is scheduled to present at the Rodman & Renshaw 17 th Annual Global Investment Conference on Thursday, September 10 th at 12:05 PM ET. The event is being held at the St. Regis Hotel in . At the time of the presentation, a live audio webcast featuring Jeff Baxter, VBI’s President and CEO, will be available at: http://bit.ly/vbi-rodman-webcast-2015 . VBI recommends registering for the webcast at least ten minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived for 90 days following the event. The Rodman & Renshaw 17th Annual Global Investment Conference features 200+ public and private companies present..."
08/26/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines to Provide an Update on its CMV Vaccine Program at the Tenth Annual IMVACS Summit CAMBRIDGE, MA – VBI Vaccines is scheduled to present at the Tenth Annual Immunotherapy and Vaccine Summit on Wednesday, August 26 th , 2015 at 4:30 PM ET. The event is being held at the Marriott Long Wharf Hotel in Boston, MA."
08/18/2015 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Securities Purchase Agreement",
"VBI Vaccines Announces Closing of $6.29 Million Private Placement CAMBRIDGE, MA – VBI Vaccines , a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets, today announced that it has closed a private placement financing led by new investor, RTW Investments, together with existing investors, ARCH Ventures Partners and Perceptive Advisors. Under the terms of the financing, VBI sold an aggregate of 3,000,000 shares of its common stock at an average price of $2.0952 per share for total gross proceeds of approximately $6.29 million. “The private placement will help strengthen VBI’s balance sheet as we further our mission of innovative vaccine formulation and development of safe and effective prophylactic and therapeutic vaccin..."
06/09/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VBI Vaccines to Present at the 2015 BIO International Convention CAMBRIDGE, MA – VBI Vaccines announced that it will be presenting at the 2015 BIO International Convention on Wednesday, June 17 th at 11:30 AM ET. Adam Buckley, VBI’s Vice President of Business Development, will discuss VBI’s eVLP and Thermostable LPV™ technologies, as well as opportunities for partnership. The 2015 BIO International Convention will be held in Philadelphia, PA, and will host thousands of organizations, including leading life sciences companies, top CROs and CMOs, more than 300 academic institutions, and major research labs and government agencies. To learn more visit: http://bit.ly/bio-2015 About VBI Vaccines Inc. VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies that seek..."
06/03/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Contacts"
05/15/2015 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy